These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118 [TBL] [Abstract][Full Text] [Related]
6. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N Urol J; 2009; 6(2):101-8. PubMed ID: 19472128 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800 [TBL] [Abstract][Full Text] [Related]
8. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis]. Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066 [TBL] [Abstract][Full Text] [Related]
9. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804 [TBL] [Abstract][Full Text] [Related]
10. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122 [TBL] [Abstract][Full Text] [Related]
11. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y Hum Pathol; 2006 Dec; 37(12):1568-76. PubMed ID: 16949911 [TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas. Kitsukawa S; Aoyagi T; Noda K; Ito T; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T Hinyokika Kiyo; 2008 Feb; 54(2):101-6. PubMed ID: 18323166 [TBL] [Abstract][Full Text] [Related]
13. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Shariat SF; Palapattu GS; Karakiewicz PI; Rogers CG; Vazina A; Bastian PJ; Schoenberg MP; Lerner SP; Sagalowsky AI; Lotan Y Eur Urol; 2007 Jan; 51(1):152-60. PubMed ID: 17011114 [TBL] [Abstract][Full Text] [Related]
14. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. Steven K; Poulsen AL J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113 [TBL] [Abstract][Full Text] [Related]
15. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120 [TBL] [Abstract][Full Text] [Related]
16. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418 [TBL] [Abstract][Full Text] [Related]
18. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Wright JL; Lin DW; Porter MP Cancer; 2008 Jun; 112(11):2401-8. PubMed ID: 18383515 [TBL] [Abstract][Full Text] [Related]
19. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744 [TBL] [Abstract][Full Text] [Related]
20. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. Bastian PJ; Hutterer GC; Shariat SF; Rogers CG; Palapattu GS; Lotan Y; Vazina A; Amiel GE; Gupta A; Sagalowsky AI; Lerner SP; Schoenberg MP; Karakiewicz PI; BJU Int; 2008 Feb; 101(4):450-4. PubMed ID: 17850359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]